5-year follow-up study of patients who initiated pembroliZumab for the treatment of advanced melanoma during its temporary authorization for use (ATU).

{
"level_sex_clusion_I": [
"Male",
"Female"
],
"level_age_clusion_I": [
"Young Adult (19 to 24 years)",
"Adult (25 to 44 years)",
"Middle Aged (45 to 64 years)",
"Aged (65 to 79 years)",
"Aged, 80 and over (80 years and more)"
],
"level_type_clusion_I": [
"Patients population"
],
"level_type_clusion_other": "",
"clusion_I": "",
"clusion_E": ""
}